Elicitation of health state utilities in soft tissue sarcoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Soft tissue sarcomas (STS) are uncommon tumours with varying histological subtypes. There is a paucity of available data concerning the quality-of-life (QoL) impact of STS which could be used to support economic evaluation of future treatments. This study aimed to elicit societal utility values for health states that depict the impact of STS and its treatment.
Following the development of eight health state vignettes, a sample of 100 members of the UK general public participated in a valuation exercise to elicit utility values using the time trade-off procedure.
The treatment response state was valued as the least burdensome by participants followed by the prospect of stable disease (mean utility value: 0.736 SD 0.21). Serious adverse events were associated with a range of disutilities from −0.236 for grade III/IV pain to −0.357 for grade III/IV nausea/vomiting. Progressive disease was deemed the least desirable outcome and was associated with a substantial decline in utility (−0.473).
Findings suggest advanced STS are associated with significant burden for individuals. Treatment-related adverse events were seen as debilitating, however, progression represents an enormous challenge to QoL. This illustrates the significant value to individuals of extending the progression free survival period.
- Carter, N. J., & Keam, S. J. (2010). Trabectedin a review of its use in soft tissue sarcoma and ovarian cancer. Drugs, 70(3), 355–376. CrossRef
- Vincenzi, B., Frezza, A. M., Santani, D., et al. (2010). New therapies in soft tissue sarcoma. Expert Opinion, 15(2), 237–248.
- Casali, P. G., Jost, L., Sleijfer, S., et al. (2008). Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Supp 2), 89–93.
- Hensley, M. L. (2010). Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Current Opinion in Oncology, 22, 356–361. CrossRef
- National Cancer Institute, Surveillance Epidemiology and End Results (NCI SEER), 2008. Available from: http://seer.cancer.gov/statfacts/html/soft.html Accessed on 10 December 2011.
- Parsons, J. A., & Davis, A. M. (2004). Rehabilitation and quality-of-life issues in patients with extremity soft tissue sarcoma. Current Treatment Options in Oncology, 5, 477–488. CrossRef
- Peiper M., Matthaei H., Bölke E., Zurakowski D., Orth K., Heinecke A., et al.(2011) Compartmental resection for subfascial extremity soft tissue sarcoma and quality of life in long-term survivors. Wien Klin Wochenschr doi: 10.1007/s00508-011-1592-5.
- Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72. CrossRef
- National Institute of Health and Clinical Excellence (NICE). (2008). Guide to the methods of technology appraisal. London: NICE.
- Kontodimopoulos, N., Aletras, V. H., Paliouras, D., et al. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health, 12, 1151–1157. CrossRef
- Crott R., Briggs A. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ;11(4):427–34. Epub 2010 May 16.
- Petrill, J., & Cairns, J. (2008). Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Review on Pharmacoecon Outcomes Research, 8(5), 453–461. CrossRef
- Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5, 1–30. CrossRef
- Office of National Statistics (ONS), Website: (2001) Population of the United Kingdom: by ethnic group: http://www.ons.gov.uk/ons/index.html. Accessed on 09 December 2011.
- Lloyd, A., Nafees, B., Narewska, D. S., & Watkins, J. (2006). Health state utilities for metastatic breast cancer. British Journal of Cancer, 95, 683–690. CrossRef
- Nafees, B., Stafford, M., Gavriel, S., Bhalla, S., & Watkins, J. (2008). Health state utilities for non-small cell lung cancer. Health and Quality of Life Outcomes, 6, 84. CrossRef
- Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998). Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ, 316, 736. CrossRef
- Launois, R., Reboul-Marty, J. M., Henry, B., & Bonneterre, J. (1997). A cost/utility analysis of second line chemotherapy in metastatic breast cancer. Pharmaco Economics, 11(5), 495–497. CrossRef
- Kattan, M. W., Cowen, M. E., & Miles, B. J. (1997). A decision analysis for treatment of clinically localized prostate cancer. Journal of General Internal Medicine, 12(5), 299–305. CrossRef
- Swinburn, P., Lloyd, A., Nathan, P., Choueiri, T. K., Cella, D., & Neary, M. (2010). Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion, 26(5), 1091–1096. CrossRef
- Coghill D., et al. (2004) Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP).
- Lloyd A. (2011). Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations Patient; 4 (4): 247–257.
- Ubel, P. A., Loewenstein, G., & Jepson, C. (2003). Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Quality of Life Research, 12, 599–607. CrossRef
- Kostopoulou, O. (2006). The transient nature of utilities and health preferences. Medical Decision Making, 26, 304–306. CrossRef
- Dolan, P., & Kahneman, D. (2008). Interpretations of utility and their implications for the valuation of health. The Economic Journal, 18, 215–234.
- Blumenschein K., Blomquist G., Johannesson M. et al. Eliciting willingness to pay without bias: Evidence from a field experiment. The Economic Journal; 18: 114–137.
- Elicitation of health state utilities in soft tissue sarcoma
Quality of Life Research
Volume 22, Issue 7 , pp 1697-1706
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Soft tissue sarcoma
- Health-related quality of life
- Economic evaluation
- Industry Sectors